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Summary
Objective: Osteoarthritis (OA) is the most common form of arthritis and a primary cause of disability, however, there are no treatments that can
slow disease progression or repair damaged joint cartilage. Fibroblast growth factor-18 (FGF18) has been reported to have signiﬁcant
anabolic effects on cartilage. We therefore examined its effects on repair of cartilage damage in a rat meniscal tear model of OA.
Design: Surgical damage to the meniscus in rats leads to joint instability and signiﬁcant damage to the articular cartilage at 3 weeks post-
surgery. At this time, animals received bi-weekly intra-articular injections of FGF18 for 3 weeks, and the knee joints were then harvested for
histologic examination.
Results: FGF18-induced dose-dependent increases in cartilage thickness of the tibial plateau, due to new cartilage formation at the articular
surface and the joint periphery. The generation of new cartilage resulted in signiﬁcant reductions in cartilage degeneration scores. The highest
dose of FGF18 also induced an increase in chondrophyte size and increased remodeling of the subchondral bone.
Conclusions: The results of this study demonstrate that FGF18 can stimulate repair of damaged cartilage in a setting of rapidly progressive OA
in rats.
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SocietyIntroduction
Osteoarthritis (OA), also known as degenerative joint
disease, is a major medical problem that affects 12% of
people over the age of 25, and 50% over the age of 651,2.
Conservative estimates indicate that patients with OA in the
United States account for 46 million physician visits and 3.7
million hospital admissions with total economic costs
exceeding $15 billion per year2. Current therapy is limited
to life-style changes and palliatives, which reduce the pain
but do not slow disease progression. Cartilage loss in OA
occurs through proteoglycan depletion and chondrocyte
death, processes likely due to imbalances between
catabolic and anabolic activities within the joint3. Recent
efforts to identify agents that will alter the progression of OA
have focused on inhibition of the catabolic cascade of
cytokines and enzymes4e6 or on anabolic factors that may
stimulate repair of cartilage lesions. A number of growth
factors have been reported to have anabolic effects on
cartilage7e13 and some have shown efﬁcacy in preclinical
models of traumatic cartilage injury8,14e18. To our knowl-
edge, however, there are no reports of their efﬁcacy in an
animal model where cartilage damage arises due to joint
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Received 29 September 2004; revision accepted 2 March 2005.62instability, models that are representative of joint failure in
OA19.
A recently identiﬁed member of the ﬁbroblast growth
factor (FGF) family, FGF18, plays a central role in skeletal
growth and development20,21. Mice lacking Fgf18 exhibit
malformations in cartilage and bone, including delayed
closure of the calvarial sutures, enlargement of the pro-
liferating and hypertrophic zones in the growth plate of long
bones, defects in joint development, and delays in
osteogenic differentiation20,21. FGFs transmit their signals
through binding and activation of one of four FGF receptor
tyrosine kinases22. FGF18 activates the ‘‘IIIc’’ splice
variants of FGFR2 and FGFR3, receptors known to play
major roles in bone and cartilage biology20,21,23,24.
In contrast to its role in the growth plate, where it
negatively regulates chondrocyte proliferation and differen-
tiation20,21,25, FGF18 has been shown to have signiﬁcant
anabolic effects on chondrocytes in other cartilaginous
tissues26. Local delivery of adenovirus expressing Fgf18
into the pinnae of nude mice increased the formation of
auricular cartilage expressing high levels of type II collagen
and proteoglycans26. Systemic delivery of pharmacologic
doses of FGF18 to rats via a single intravenous injection
stimulated expansion of various cartilage depots, including
the rib-sternum junction, trachea, spine, and articular
cartilage within a 2-week period25. Similarly, overexpres-
sion of Fgf18 under the lung-speciﬁc Sp-C promoter
induced a dramatic enlargement of bronchial cartilage
expressing type II collagen27. These effects could be
due to the direct action of FGF18 on mature chondrocytes3
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differentiation. Although direct effects of FGF18 on chon-
drocyte progenitor cells have yet to be established, FGF18
has been shown to stimulate the growth and proteoglycan
synthesis of mature primary porcine and human articular
chondrocytes26 and the growth of neonatal rat costal
chondrocytes28.
To evaluate whether FGF18 could facilitate the repair of
cartilage damage caused by OA, the efﬁcacy of FGF18 was
tested in a rat meniscal tear model of OA4,29. In this model,
a full-thickness cut in the medial meniscus leads to joint
instability and progressive development of OA character-
ized by proteoglycan loss, cartilage ﬁbrillation, chondrocyte
death, eventual damage to the subchondral bone, and
formation of osteophytes4,29. In the current report, FGF18
was administered by intra-articular injection beginning 21
days after meniscal tear. FGF18 induced a dose-dependent
increase in de novo cartilage formation and a parallel
reduction in cartilage degeneration scores in the medial
tibial plateau of the OA rats. To our knowledge, these
results make FGF18 the ﬁrst anabolic agent demonstrated
to facilitate cartilage repair in an in vivo model of OA.
Methods
INDUCTION OF OA BY MENISCAL TEAR PROCEDURE
SpragueeDawley male rats (300e375 gm, Charles River,
Wilmington, MA) were housed two per cage and were
acclimated 7 days prior to use. All animals were allowed
access to food and water ad libitum before and after
surgeries. Rats were anesthetized with isoﬂurane and the
right knee prepared for surgery. A skin incision was made
over the medial aspect of the right knee, the medial
collateral ligament exposed by blunt dissection, and then
transected. A full-thickness cut was made through the
medial meniscus to simulate a complete tear. The skin and
subcutis were closed with 4-O Vicryl suture by using
a subcuticular pattern.
PREPARATION OF RECOMBINANT HUMAN FGF18
FGF18 was expressed in E. coli by using the maltose-
binding protein fusion system and puriﬁed as previously
described26.
TREATMENT WITH HYALURONAN OR FGF18
The FGF18 doses and dosing schedule used were based
on preliminary studies in normal mice where the most
consistent cartilage expansion in the marginal zones was
observed following intra-articular injection of hyaluronan
carrier containing FGF18 over the indicated dose range.
Treatment was initiated 3 weeks after surgery and continued
through week 6. Immediately prior to injection, hyaluronan
(MWZ 1.1! 106 Da, LifeCore, Chaska, MI) was freshly
prepared to a ﬁnal concentration of 1.0% in sterile
phosphate buffered saline (PBS). The hyaluronan solution
was diluted with an equal volume of sterile PBS containing
FGF18 to yield ﬁnal concentrations of 1.0, 10.0, and 50.0 mg
FGF18/ml. Animals (10 rats per group) received bi-weekly
intra-articular injections into the operated knee of 0.1 ml
of either vehicle or vehicle containing 0.1, 1.0, or 5.0 mg
of FGF18. One hour prior to the last injection (day 17 of
treatment), rats were given intraperitoneal injections of
50 mg BrdU/kg and the animals sacriﬁced 72 h later. Theright knee joints were trimmed of muscle and connective
tissue, the patellae removed, and the joints ﬁxed in 10%
neutral buffered formalin. All procedures involving animals
were approved by the authors’ institutional review boards.
HISTOLOGY AND EVALUATION
The ﬁxed joints were decalciﬁed in 0.5% formic acid and
trimmed into two equal frontal halves. Following dehydra-
tion through a graded alcohol series, the tissues were
embedded in parafﬁn, sectioned (200 mm), and stained with
Toluidine Blue. Images of the medial tibial plateaus were
captured and sections representing three levels of each
joint analyzed microscopically and scored in a blinded
fashion by a board-certiﬁed veterinary pathologist (AB). The
scoring results and conclusions were qualitatively con-
ﬁrmed by three other investigators (KSW, EEM, and JLE).
In scoring for cartilage degeneration and chondrophyte
formation, the worst-case scenario for the two halves of
each of the three levels was determined; these values were
averaged to obtain a score for each joint. Newly generated
cartilage was considered integrated with pre-existing
cartilage if the tissue remained apposed or joined during
histologic sectioning.
The tibial cartilage degeneration score was used to
measure cartilage degeneration in three equally spaced
regions across the surface of the medial tibial plateau. The
scoring system ranged from 0 to 5 with 0Z no degenera-
tion, 1Zminimal degeneration with loss of chondrocytes
and proteoglycans with or without ﬁbrillation involving the
superﬁcial zone, 2Zmild degeneration with loss of
chondrocytes and proteoglycans with or without ﬁbrillation
involving the upper 1/3 of the cartilage thickness, 3Zmo-
derate degeneration with loss of chondrocytes and proteo-
glycans and ﬁbrillation extending well into the midzone and
generally affecting 1/2 of the total cartilage thickness,
4Zmarked degeneration with loss of chondrocytes and
proteoglycans and ﬁbrillation extending into the deep zone
but with residual matrix above the tidemark, and 5Z severe
degeneration with matrix loss to the tidemark. Strict
attention to zones (outside, middle, and inside 1/3) was
adhered to in this scoring method and summed scores
reﬂect a global severity of tibial cartilage degeneration.
The signiﬁcant cartilage degeneration width was a mi-
crometer measurement of the width of the surface of the
tibial plateau in which chondrocyte and matrix loss had
extended through greater than 50% of the cartilage
thickness.
The depth ratio represents the percent of the cartilage
thickness that has been eroded by a lesion and was
determined by taking micrometer measurements of the
depth of any lesion over four equally spaced points on the
tibial surface. These measurements were taken at matrix
adjacent to the chondrophyte and at 1/4, 1/2, and 3/4 of the
distance across the tibial plateau. The depth to the tidemark
was also determined in each quadrant, and the depth ratio
is the depth of the lesion divided by the depth to the
tidemark. The depth to the tidemark was used to express
cartilage thickness across the tibial plateau.
Chondrophyte size was measured using an ocular
micrometer and the values averaged for the three sections
taken per animal. The bone and calciﬁed cartilage damage
score was used to evaluate damage to the calciﬁed cartilage
and subchondral bone with 0Z no damage, 1Z increased
basophilia at the tidemark but no fragmentation of the
tidemark and no marrow changes, 2Z increased basophilia
at tidemark with minimal to mild fragmentation of calciﬁed
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enchymal changes in marrow that involve up to 3/4 of the
total area and areas of marrow chondrogenesis may be
evident but without collapse of articular cartilage into
epiphyseal bone, 4Z increased basophilia at tidemark with
marked to severe fragmentation of calciﬁed cartilage and
mesenchymal changes in marrow that involve up to 3/4 of
the total area and articular cartilage has collapsed into the
epiphysis to a depth of %250 mm from tidemark, 5Z in-
creased basophilia at tidemark with marked to severe
fragmentation of calciﬁed cartilage and marrow mesenchy-
mal changes that involve up to 3/4 of the total area and
articular cartilage has collapsed into the epiphysis to a depth
O250 mm from the tidemark.
STAINING WITH ANTI-BRDU ANTIBODIES
To assess the effects of FGF18 on the proliferation of
cells within the rat knee joints, proliferating cells were
labeled by an intraperitoneal injection of BrdU as described
above and were detected with an anti-BrdU antibody. Fixed
tissues were prepared, embedded in parafﬁn, and sec-
tioned as described above. Tissues were de-parafﬁnized
through a series of washes with xylene and graded
alcohols. Endogenous proteases were blocked with 3%
H2O2 and the tissues were incubated in a blocking serum
(Vectastain ABC Kit, Vector Labs, Vector, UK) for 30 min.
Tissues were then incubated with a monoclonal anti-BrdU
antibody (Clone BU-1, Amersham Biosciences, Piscat-
away, NJ) used at a 1/100 dilution. After 1.0 h, tissues
were incubated for 30 min with secondary antibody and
then for 30 min with avidinebiotin complex. DAB peroxidase
indicator was added and samples incubated for 1.0 min and
counterstained with Harris’ Hemotoxylin. Immunostained
sections were evaluated for the presence of distinctively
dark BrdU-positive nuclei in articular cartilage in lesional
and non-lesional areas of the medial aspect of the knee
joints. Staining was also assessed in the articular cartilage
of the lateral aspect of the joint, the marginal zones and
synovium of both the medial and lateral aspects of the joint.
Speciﬁcity was assessed by staining sections of normal rat
knee joints that had not been exposed to BrdU.
STATISTICAL ANALYSIS
Inter-group analyses were performed by comparing group
means using the two-tailed Student’s t test with Bonferroni’s
correction for multiple comparisons or by analysis of
variance (ANOVA) with signiﬁcance set at P% 0.05.
Results
There were neither treatment-related alterations nor
immediate post-surgical irregularities in animals of any
group. All rats resumed weight bearing immediately after
surgery upon recovery from anesthesia. There were no
deaths and no obvious systemic effects of FGF18 treatment
observed by gross visual inspection of the animals. No
signiﬁcant differences in body weights were noted between
the groups with ﬁnal body weights of 458G 13, 469G 7,
467G 10, and 457G 8 (meanGSE, nZ 10 rats per
group) for rats in the 0, 0.1, 1.0, and 5.0 mg FGF18 dose
groups, respectively.
Sham- and vehicle-treated animals exhibited a range
of cartilage degeneration with no statistically signiﬁcant
differences observed between the two groups. In no casewas substantial ﬁlling of the defects with repair tissue
observed. Some variability in the response to meniscal tear
was observed (Fig. 1), observations that were probably
related to activity level and joint loading of the individual
rats. Similar to previous reports4,29, however, damage to the
cartilage of the medial tibial plateau was most consistent
and extensive on the outer 1/3 or weight-bearing region.
Little damage was noted on the inner 1/3 of the medial tibial
plateau (Fig. 1). In some cases, cartilage degeneration was
very severe with resorption of subchondral bone that
resulted in collapse of the articular cartilage into the
epiphysis [Fig. 1(a)], while in other subjects, cartilage
damage was less severe with lesions presenting as loss
of proteoglycan staining and surface ﬁbrillation [Fig. 1(b, c)].
In other cases, damage was severe with loss of cartilage to
the tidemark while the subchondral bone remained largely
intact [Fig. 1(d)]. Joints from the vehicle-treated animals
generally had no evidence of cartilage repair except in the
case where subchondral bone resorption in the area of the
lesion was extensive and marrow progenitor cells had
proliferated into the defect [Fig. 1(a), green arrow]. Also
typical of this instability model are the tibial and femoral
chondrophytes that were observed in all of the vehicle-
treated rats at the time of sacriﬁce [Fig. 1(aed)]. These
structures were classiﬁed as chondrophytes rather than
osteophytes because the tissue was predominately carti-
laginous with no evidence of vessel invasion or endochon-
dral bone formation at this time.
Intra-articular injection of FGF18 induced a dose-
dependent increase in cartilage hypertrophy and over-
growth of new cartilage around the damaged areas
[Fig. 1(eeh)] as well as in the lateral compartment. Repair
tissue appeared to originate from the marginal zone areas
and extended across the degraded and sometimes intact
surfaces. In addition, FGF18 increased chondrocyte pro-
liferation and extracellular matrix production, as evidenced
by an increase in chondrocyte cloning and Toluidine Blue
staining around chondrocyte clusters within the articular
surface and marginal zone cartilages (Figs. 1 and 2). In
cases where collapse of the subchondral bone had
occurred, FGF18 treatment appeared to stimulate the
formation of chondral tissue that ﬁlled the defect
[Fig. 2(a)]. By light microscopy, the morphology of the
repair tissue ranged from ﬁbrous with proteoglycan de-
position to ﬁbrocartilage. Consistent with this, visualization
of the repair tissue by polarized light microscopy demon-
strated abundant collagen formation with patterns sugges-
tive of type I or ﬁbrocartilage in many areas (data not
shown). Although the cellular organization of the newly
generated cartilage did not morphologically resemble
mature hyaline cartilage at this time, it appeared to ﬁll the
defects with virtually no degenerative changes. In nearly all
areas, the repair tissue appeared to integrate well with the
margins of the remaining normal cartilage. Other treatment-
related changes, including modest increases in synovial
hyperplasia observed by light microscopy of tissue sections
and mild joint swelling that was evident by gross visualiza-
tion of the injected knee joints that began during week two
of treatment, were noted only in rats in the 5.0 mg FGF18
dose group.
To evaluate the effects of FGF18 on cell proliferation,
animals were administered BrdU 3 days prior to sacriﬁce. In
OA rats treated with vehicle alone, little or no staining was
observed in the area of the degenerative lesions on the
medial tibial plateau, or on femoral articular surfaces
[Fig. 3(a, b)]. There was also little or no staining for BrdU
in the marginal zones, synovium, or chondrocytes in the
626 E. E. Moore et al.: FGF18 stimulates cartilage repairFig. 1. Intra-articular injection of FGF18 induced chondrogenesis and promoted repair of cartilage lesions in rats with meniscal tear-induced
OA. Rats were subjected to meniscal tear and treatment with either vehicle alone (aed) or vehicle containing 5.0 mg of FGF18 (eeh) as
described under Methods. Photomicrographs of Toluidine Blue-stained frontal sections of the medial tibia plateaus from four representative
rats from each of the two treatment groups are shown. (aed) Black arrows indicate sites of cartilage damage; red arrows indicate
chondrophytes; green arrow in (a) indicates collapse of the subchondral bone. (eeh) Black arrowheads indicate sites of chondrogenesis and
repair of cartilage lesions; red arrows represent chondrophytes. Higher magniﬁcation views of the boxed areas in (e) and (h) are shown in
Fig. 2(a) and (b), respectively. FZ femur, TZ tibia.
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the vehicle-treated rats (data not shown). In contrast, BrdU-
immunopositive chondrocytes were easily detected in the
pre-existing cartilage in OA rats treated with the 5.0 mg
doses of FGF18 [Fig. 3(c, d)]. BrdU-positive cells were also
present in the ﬁbrocartilage in the central area of the lesions
[Fig. 3(c, e)] and within the newly generated cartilage at the
margins of the joint. Little or no staining was observed, in
contrast, in the subchondral bone marrow and in areas of
synovial proliferation (data not shown).
The anabolic effects of FGF18 were quantiﬁed by
measuring the thickness of the articular cartilage in four
equally spaced zones across the surface of the medial tibial
plateau. The trophic effects of FGF18 were most dramatic in
the outer 1/4 of the tibial plateau (area of greatest damage),
where high dose FGF18 produced a 47% increase in
cartilage thickness (Table I). FGF18 produced statistically
signiﬁcant, but less robust, increases in cartilage thickness
in the central zones, and had no apparent effects on
thickness of the inner quadrant, the area of least meniscal
tear-induced damage (Table I). Across all four zones,
FGF18 produced a dose-dependent 31% increase
(PZ 0.048) in tibial cartilage thickness.
FGF18-induced de novo cartilage formation was paral-
leled by reductions in cartilage degeneration scores. In
Fig. 2. FGF18-induced chondrocyte proliferation and matrix
deposition in rats with OA. Higher magniﬁcation views of the
boxed areas in Fig. 1(e) and (h) are shown in (a) and (b),
respectively. Black arrows: chondrocyte proliferation and matrix
deposition. Yellow arrowhead: integration of FGF18-induced
cartilage repair tissue with the articular surface.vehicle-treated animals, the tibial cartilage degeneration
scores decreased from 3.23G 0.34 in the outer 1/3 to
2.83G 0.3 and 1.17G 0.14 in the middle 1/3 and inner 1/3,
respectively (meanG S.E.M., P! 0.0001), thus verifying
that the greatest damage occurred on the outer 1/3 of the
medial tibial plateau. Treatment with FGF18 produced
dose-dependent reductions in the degeneration scores for
the outer 1/3 of the medial tibia plateau (Table II), resulting
in a 56% decrease at the highest dose of FGF18. Although
little or no effect of FGF18 on degeneration scores was
observed for the middle 1/3 and inner 1/3 (areas of least
damage) of the medial tibia plateau (Table II), total cartilage
degeneration scores were reduced 28% (PZ 0.029) in OA
rats treated with the highest dose of FGF18.
Signiﬁcant tibial cartilage degeneration, where chondro-
cyte and matrix loss extended through greater than half of
the cartilage thickness, was reduced 57% by treatment with
the 5.0 mg doses of FGF18 (Table II). Similarly, treatment
with FGF18 produced a 46% dose-dependent reduction in
the depth of cartilage lesions (Table II). Relative to sham-
injected rats, the vehicle alone had little effect on cartilage
degeneration scores (data not shown).
In addition to the anabolic effects at the articular surface,
intra-articular administration of FGF18 also produced dose-
dependent increases in medial tibial chondrophyte meas-
urements due to enhanced chondrocyte proliferation and
extracellular matrix deposition at the marginal zones of the
articular surface (Fig. 1). For the 0, 0.1, 1.0 and 5.0 mg
FGF18 dose groups, the medial tibial chondrophyte
measurements were 602.0G 49, 579G 35, 875G 121,
and 915G 51 mm, respectively (meanG S.E.M., P! 0.0005
by ANOVA). Relative to sham injection, intra-articular
injection of vehicle alone produced no signiﬁcant change
in chondrophyte measurements (data not shown). The
subchondral bone scores, indicative of bone resorption/
remodeling, were not statistically different in rats treated
with vehicle or vehicle containing the 0.1 and 1.0 mg doses
of FGF18. Intra-articular injection of vehicle containing the
highest dose of FGF18 produced, however, a modest
elevation of bone scores, from 3.5G 0.31 to 4.6G 0.16
(meanG S.E.M., PZ 0.012) in rats treated with vehicle or
FGF18, respectively.
Discussion
The data presented in this report demonstrate that intra-
articular administration of FGF18 can promote repair of
cartilage damage in a rat meniscal tear model of OA.
FGF18 treatment was initiated 3 weeks after surgical
damage to the meniscus at a point when there was
signiﬁcant erosion of the articular surface of the medial
tibial plateau. A subsequent 3-week treatment with FGF18
induced a dose-dependent increase in cartilage formation
and a statistically signiﬁcant increase in the thickness of the
articular surface of the medial tibial plateau. The increase in
cartilage formation induced by FGF18 was paralleled by
signiﬁcant reductions in multiple degeneration scores.
Histologic analysis of joint sections stained with H&E and
Toluidine Blue suggested that the newly generated cartilage
induced by FGF18 at this time resembled a mixture of
ﬁbrous- and hyaline-like cartilage. At this early time point in
the repair process, the newly generated cartilage probably
represents primitive repair tissue that may undergo remod-
eling over time. By light microscopy, the repair tissue
appeared to be remarkably well integrated with the
surrounding normal cartilage with few clefts or spaces
628 E. E. Moore et al.: FGF18 stimulates cartilage repairFig. 3. BrdU immunostaining in osteoarthritic rats treated with vehicle or FGF18. Rats with meniscal tear were treated with either vehicle (a and
b) or vehicle containing 5.0 mg FGF18 (cee), BrdU was administered, tissue sections were prepared, and stained with anti-BrdU antibodies as
described under Methods. (a) Low magniﬁcation (100!) of medial side of knee of rat with meniscal tear treated with vehicle alone. Blue
arrows show chondrocyte clones. Black arrow denotes the tibial tidemark. (b) Higher magniﬁcation (400!) shows medial tibial lesion with cell
loss and cloning (black arrows). (c) Low magniﬁcation (100!) of medial tibial defect. Black arrows identify junction of cartilage with ﬁbrous
repair tissue. Blue arrows identify BrdU-positive chondrocyte nuclei. (d) Higher magniﬁcation (400!) of BrdU-positive (Blue arrows)
chondrocyte nuclei in (c). (e) Higher magniﬁcation (400!) of ﬁbrous repair tissue in central area of defect shown in (c). Blue arrows identify
immunopositive ﬁbroblast-like cells. Green arrow identiﬁes faintly labeled ﬁbroblast nucleus. FZ femur, TZ tibia.observed between the new and old tissue. Such integration
is considered essential for the long-term survival of cartilage
repair tissue30,31. Although the results of the current study
demonstrate that FGF18 can stimulate cartilage formation
in this model of OA, additional studies are required to
assess the long-term durability and maturity of the newly
formed tissue. Of particular interest will be the expression
pattern of Col1 (ﬁbrocartilage), Col2 and aggrecan (hyaline
cartilage), Col2A (chondro-progenitor cells), and Col10
(hypertrophic chondrocytes).
The reparative effects observed with FGF18 can probably
be attributed to its interaction with multiple target cells within
the joint. While a detailed mechanism for these effects is not
yet understood, the data are consistent with previous in vitro
observations that FGF18 stimulated the proliferation
of mature articular chondrocytes and increased theirproduction of extracellular matrix26. In the present study,
FGF18 appeared to stimulate proliferation of mature
chondrocytes within the superﬁcial layer of both the medial
and lateral articular surface, as evidenced by increased
chondrocyte cloning and increased incorporation of BrdU.
In addition, less mature repair tissue appeared to be
induced by FGF18 at the margins of the joint and extended
over the articular surface. The source of this tissue is not
clear but it is likely that it was generated from mesenchymal
chondro-progenitor cells that are thought to reside in
the perichondrium, periosteum, and/or synovium17,32e38.
The chondrophytes or osteophytes that are observed in the
margins of destabilized joints are also thought to arise from
chondro-progenitor cells39, and the size of the chondro-
phytes observed in this study was increased by treatment
with FGF18. As used by Gelse et al.39 to describe early
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FGF18 increased the thickness of articular cartilage in the medial tibial plateau of rats with meniscal tear-induced OA
FGF18 dose group
(mg/injection)
Medial tibial cartilage thickness (mm)
Zone 1 Zone 2 Zone 3 Zone 4
0 210.7 (26.9) 205.3 (15.7) 234.7 (32.5) 329.7 (23.1)
0.1 227.7 (34.0) 209.3 (16.5) 244.0 (35.9) 312.4 (43.3)
1.0 277.0 (54.8) 239.0 (43.3) 268.7 (80.0) 316.3 (27.8)
5.0 309.0 (106.0)* 275.6 (70.7)** 376.3 (167.6)y 320.7 (39.1)
The values represent the mean values for each group with the SD in parentheses. Differences were signiﬁcant for each zone relative to
vehicle-treated rats: *PZ 0.0046, **PZ 0.0206, yPZ 0.047 by ANOVA. Zones 1e4 represent the outer to inner 1/4, respectively, of the
medial tibial plateau as described under Methods.stage human osteophytes, the term chondrophyte, rather
than osteophyte, was used in the present study to describe
the cartilaginous growths at the joint margins. Since
osteophyte development appears to be a sequential pro-
cess39, it is possible that the chondrophytes would undergo
endochondral ossiﬁcation with more time. However, little or
no vessel invasion or bone formation was observed within
the cartilaginous outgrowths over the time course of the
present study. Additional long-term studies will clearly be
required to resolve this issue. The highest dose of FGF18
induced a modest increase in subchondral bone remodel-
ing, and in those instances where the lesions extended
through the subchondral bone, FGF18 appeared to induce
the formation of hyaline-like cartilage in subchondral bone
cysts, most likely by stimulating the differentiation of the
resident bone marrow mesenchymal stem cells.
There were no invading blood vessels within the joint
space in either the vehicle or FGF18-treated animals,
even in those instances where the subchondral bone had
collapsed into the bone marrow space. Thus, despite the
fact that angiogenesis is considered to be essential for most
wound healing40, the induction of new cartilage formation by
FGF18 appears to be independent of vessel invasion.
Indeed, signiﬁcant angiogenesis within the joint would likely
trigger the conversion of the newly generated cartilage
into bone41. The lack of vessel invasion in the FGF18-
treated joints is consistent with other in vitro and in vivo
observations that FGF18 does not have any signiﬁcant
angiogenic activity (Moore EE, Gilbertson D, Garcia R, and
Ellsworth JL, unpublished observations).
Whether the mild joint swelling that was observed in rats
during the second week of treatment with the highest dose
of FGF18 is related to proliferation of synovial and/or
chondral tissue, or to other factors, is not clear. Swelling
could be a general response to FGF18-mediated induction
of cell proliferation within the joint, a local inﬂammatoryresponse to injection of foreign protein into the joint space,
or could be an intrinsic property of FGF18. While a modest
degree of synovial hyperplasia was seen in animals treated
with the highest dose of FGF18, cells within this tissue did
not appear to incorporate the BrdU label to any signiﬁcant
degree. This apparent discrepancy is likely related to the
timing of FGF18 and BrdU administration. Future studies of
the time course of the FGF18 response should assist in
resolving these issues.
In contrast to the results described here, we found that
a similar treatment regime with FGF18 did not increase
chondrocyte proliferation and matrix accumulation in the
articular cartilage surface of normal rat knee joints, nor was
there any signiﬁcant increase in the thickness of the
articular cartilage (Moore EE, Bendele AM, and Ellsworth
JL, unpublished observations). This difference suggests
that FGF18 may exert anabolic activities speciﬁcally
following injuries or may be a speciﬁc response to tissue
injury. Similarly, FGF2 has been reported to stimulate
chondrocyte clustering and extracellular matrix production
in a partial chondral defect model, but not in normal rabbit
joints8. One possible explanation for the increased activity
of FGF18 in the injured joint is that it may have more ready
access to its target cells due to the loss of matrix and
ﬁbrillation of the cartilage. Another possibility is that the
anabolic activity of FGF18 may be enhanced by other
growth factors or cytokines that are released into the
injury milieu. These could include either factors such as
interleukin-1 (IL-1)5 and insulin-like growth factor-1 (IGF-1)7,
the concentration of which are known to be elevated in the
synovial ﬂuid of patients with OA, or factors that are known
to have anabolic effects on cartilage, such as transforming
growth factor-b (TGF-b) and bone morphogenic protein-2
(BMP-2)9. Indeed, a recent report suggests that FGF18 may
facilitate the chondrogenic activity of the BMPs by
suppressing the expression of noggin, a naturally occurringTable II
FGF18 reduced cartilage degeneration scores in the medial tibial plateau of rats with meniscal tear-induced OA
FGF18 dose group
(mg/injection)
STCDW
(mm)
DR TCDS
Zone 1 Zone 2 Zone 3
0.0 577 (100) 0.45 (0.05) 3.23 (0.34) 2.83 (0.3) 1.17 (0.14)
0.1 477 (96) 0.36 (0.04) 2.57 (0.39) 2.37 (0.17) 0.70 (0.10)y
1.0 417 (88) 0.34 (0.04) 1.93 (0.24) 2.93 (0.19) 1.10 (0.18)
5.0 247 (50)*,x 0.25 (0.03)z 1.40 (0.18){ 2.67 (0.21) 1.23 (0.21)
The abbreviations used are: STCDW, signiﬁcant tibial cartilage degeneration width; DR, depth ratio; TCDS, medial tibial cartilage
degeneration score. Zones 1e3 refer to the outer, middle, and inner 1/3 of the medial tibial plateau. Each value represents the mean with the
S.E.M. in parentheses. Differences were signiﬁcant comparing vehicle and FGF18 treatment groups (*PZ 0.015, yPZ 0.0137) using an
unpaired Student’s two-tailed t test. Differences were signiﬁcant relative to vehicle (zPZ 0.012, xPZ 0.067, {P! 0.0008) by ANOVA.
630 E. E. Moore et al.: FGF18 stimulates cartilage repairinhibitor of BMP signaling42. Thus, FGF18 may work in
concert with other factors within the joint to promote the
repair of cartilage damage in OA.
The effects induced by FGF18 in this model are
reminiscent of the endogenous repair response that is
observed during the early stages of OA. Early loss of
extracellular matrix is often followed by a transient episode
of chondrocyte proliferation as well as increased matrix
production both within the lesion site and in the superﬁcial
zone of the adjacent articular cartilage43. Destabilization of
the joint through injury or disease also produces thickening
of the marginal zone cartilage and the generation of
chondrophytes or osteophytes43. The fact that FGF18
appears to stimulate both of these processes suggests that
it may enhance the normal reparative response of articular
cartilage to injury. Whether these results in the rat, a rapidly
growing animal, can be extrapolated to other species is not
yet clear.
Although the receptors that mediate FGF18-induced
expansion of articular cartilage observed in the present study
have not yet been established, FGF18 activates the (IIIc)
splice variants of FGFR2 and FGFR326 and both of these
receptor genes are expressed in chondrocytes of mature
articular cartilage26. Expression of Fgfr2-(IIIc) has also been
observed in developing periosteum, perichondrium, and
endosteum20,23,44, suggesting a role for FGFR2-(IIIc) in
FGF18-mediated expansion of marginal zone cartilage
proliferation. These conclusions must be tempered by the
fact that little is known of FGF receptor expression in various
cells of adult joint tissues.
Several other growth factors have been reported to have
anabolic effects on cartilage including IGF-1, osteogenic
protein-1 (OP-1), TGF-b, hepatocyte growth factor (HGF),
and FGF27e13. All these factors have been reported to
enhance repair of full-thickness osteochondral defects14e16,
and OP-1, TGF-b1 and FGF2 have reported efﬁcacy in
partial thickness chondral defect models as well8,17,18.
Despite the apparent efﬁcacy of these factors in chondral
defect models of traumatic cartilage injury, however, there
are no reports of their efﬁcacy in an animal model of OA.
Hence, the current results with FGF18 represent the ﬁrst
example of an anabolic factor that can stimulate formation
of new cartilage in an animal model of OA, and suggest that
FGF18 may have clinical utility for treatment of this disease.
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